Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Queen Mary University of London
Modality
monoclonal_antibody
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05688436CT.gov A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies | — | Active Not Recruiting | — | — | — |
NCT03477500CT.gov Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS) | — | Active Not Recruiting | — | — | — |
NCT03368664CT.gov A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT | — | Terminated | — | — | — |
NCT04082260CT.gov Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers for Risk Stratification and Treatment Response | — | Unknown | — | — | — |
NCT01624714CT.gov Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced Subjects | — | Unknown | — | — | — |
NCT01712945CT.gov Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis | — | Terminated | — | — | — |
NCT00278655CT.gov Hematopoietic Stem Cell Therapy for Patients With Multiple Sclerosis | — | Terminated | — | — | — |
NCT06705608CT.gov Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Multiple Sclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Alemtuzumab (this asset) | Queen Mary University of London | Approved | BB · 65 |
| Cladribine | University Hospital, Strasbourg, France | P4 | BBB |
| Nabiximols | Jazz Pharmaceuticals | P4 | BBB |
| Teriflunomide | Sanofi | P4 | BBB |
| Ocrelizumab | Polpharma Biologics International AG | P4 | BBB |
| Fampridine | MGH Institute of Health Professions | P4 | BBB |
| Natalizumab | Biogen | P4 | BB |
| Fingolimod | Biogen | P4 | BB |
| Interferon ?1 (Human Fibroblast Protein Moiety) | Bayer | P4 | BB |
+42 more in the Multiple Sclerosis cohort
Other indications for Alemtuzumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Relapsing-Remitting Multiple Sclerosis | — | P4 | BBB · 73 |
| Myelodysplastic/Myeloproliferative Neoplasm | — | P2 | BB · 71 |
| Chronic Myeloid Leukemia | — | P2/3 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Alemtuzumab in Multiple Sclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-human-rat-monoclonal-campath-1h-gamma1-chain-anti-human-antigen-cd52-disulfide-with-human-rat-monoclonal-campath-1h-light-chain-dimer-multiple-sclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →